Mark G. Kris, MD

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays.

Oncologists explain scenarios for which they may retest patients previously assessed via genomic profiling.

How to determine what information from comprehensive genomic profiling assays is relevant vs extraneous when making treatment decisions for patients with solid tumor cancers.

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

How the identification of certain driver mutations analyzed by genomic assays can be applied into oncology treatment.

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.